Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Feb 2:2:195-200.
doi: 10.2147/ppa.s2356.

Erythropoietin stimulating agents in the management of anemia of chronic kidney disease

Amir Hayat  1 , Dhiren Haria, Moro O Salifu
Affiliations

Erythropoietin stimulating agents in the management of anemia of chronic kidney disease

Amir Hayat et al. Patient Prefer Adherence. .

Abstract

Anemia is a very common clinical problem in patients with chronic kidney disease (CKD) and is associated with increased morbidity and mortality in these patients. Erythropoietin is a hormone synthesized in the kidney responsible for red blood cell maturation in the bone marrow. It is deficient in the majority of patients with advanced kidney disease thereby predisposing to anemia. Since the approval of recombinant human erythropoietin (epoetin alfa) by the US FDA in 1989, epoetin alfa and similar agents now collectively known as erythropoietin stimulating agents (ESA) have become the standard of care for the treatment of the erythropoietin-deficient anemia that occurs in most patients with CKD. In this review, we have outlined the considerations that need to be taken into account when prescribing ESA for the treatment of anemia in CKD.

Keywords: anemia; chronic kidney disease; erythropoietin stimulating agents.

PubMed Disclaimer

References

    1. Barany H-J, Muller Maintaining control over haemoglobin levels: optimizing the management of anaemia in chronic kidney disease. Nephrol Dial Transplant. 2007;22(Suppl 4):iv10–iv18. - PubMed
    1. Brugnara C. Iron deficiency and erythropoiesis: new diagnostic approaches. Clin Chem. 2003;49:1573–8. - PubMed
    1. Collins AJ, Ma JZ, Ebben J. Impact of hematocrit on morbidity and mortality. Semin Nephrol. 2000;20:345. - PubMed
    1. Coyne DW, Kapoian T, Suki W, et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the dialysis patients’ response to IV iron with elevated ferritin (DRIVE) study. J Am Soc Nephrol. 2007;18:975. - PubMed
    1. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–84. - PubMed

LinkOut - more resources